Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911263 | 0.88 | PDGFRB (0.65) | SYKPDGFRBPDGFRATRPV1EGFR | |
| SCHEMBL2921459 | 0.88 | PDGFRB (0.54) | SYKPDGFRBPDGFRATRPV1CDK4 | |
| SCHEMBL2921831 | 0.87 | PDGFRB (0.54) | SYKPDGFRBPDGFRATRPV1CDK4 | |
| SCHEMBL2917218 | 0.86 | PDGFRB (0.63) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2912670 | 0.85 | PDGFRB (0.65) | SYKPDGFRBPDGFRACDK4CCND1 | |
| SCHEMBL2917783 | 0.83 | PDGFRB (0.49) | SYKPDGFRBPDGFRACDK4CCND1 | |
| SCHEMBL2922682 | 0.81 | PDGFRB (0.48) | SYKPDGFRBPDGFRACDK4CCND1 | |
| SCHEMBL12999433 | 0.78 | KDR (0.52) | SYKPDGFRBPDGFRACDK2EGFR | |
| SCHEMBL12999479 | 0.78 | SYK (0.59) | SYKPDGFRBPDGFRACDK2EGFR | |
| SCHEMBL2912421 | 0.77 | CDC7 (0.52) | SYKPDGFRBPDGFRACDK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009084695-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | SYK 724/4885PDGFRB 1018/4885PDGFRA 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.